We cannot rule out that some of it is caused by a higher smoking prevalence in the β2AR agonist users compared to non-users, also after removal of COPD patients, but it seems unlikely given that individuals with asthma do not smoke more than the general population [30,31]. The gene discussed is ADRB2; the disease is chronic obstructive pulmonary disease.